Cost of care in Iranian hemophilic patients

AUTHORS

M Karimi 1 , * , S Rahmani 2 , R Ardeshiri 2 , A RahmanAttar 2 , M Pasalar 2

1 Professor of Pediatric Hematology and Oncology,Hematology Research Center,Nemazee Hospital,School of Medicine,Shiraz University of Medical Sciences, karimim@sums.ac.ir, Fars, Iran

2 Hemostasis and Thrombosis Unit,Hematology Research Center,Nemazee Hospital,Shiraz University of Medical Sciences, Fars, Iran

How to Cite: Karimi M, Rahmani S, Ardeshiri R, RahmanAttar A, Pasalar M. Cost of care in Iranian hemophilic patients, Iran Red Crescent Med J. Online ahead of Print ; 9(3):154-157.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 9 (3); 154-157
Article Type: Brief Report

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Lifetime treatment of persons with hemophilia entails a heavy financial burden. The main goal of this study was to determine the factors influencing care cost of hemophilia A in southern Iran.

 

Methods: The present study comprised 88 of 170 hemophilia A patients who had been registered and virtually treated in Fars Hemophilia Treatment Center in southern Iran. The data concerning patients’ characteristics and medication schedules were collected from their past medical records and staff interviews. The scale utilized by the Hemophilia Utilization Group Study (HUGS) was used to assess the status of patients’ functional health.

 

Results: The severe, moderate and mild deficiencies of factor VIII were found in 43.2%, 21.6% and 35.2% of 88 patients respectively. The mean age in the study group was 21.8 years (±12.2) and 58 (65.9%) enjoyed high health status. In regard to laboratory records, 25 (28.4%) patients were HCV-positive, 2 (2.3%) HBS-positive and all were HIV negative. The average cost of care for a patient with Hemophilia A was $8,510 (±8,066) and the total annual costs were significantly (p< 0.05) associated with: severity of arthropathy, presence of factor VIII inhibitor and its titer, severity of factor VIII deficiency, positive HCV infection and functional health status. Costs unrelated to foregoing factors included only 1% of the total.

 

Conclusion: The total cost of patient care was correlated with severity of factor deficiency, arthropathy, positive HCV infection and functional health status. Financial resources to meet factor-unrelated costs should increase, in order to provide patients with improved quality of medical care.

Keywords

Cost of care Hemophilia A Iran

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: